Alembic Pharmaceuticals Share Price
802.10-1.55 (-0.19%)
-16.08% past 1 Year
News
Alembic Pharmaceuticals schedules investor and analyst meets on 1st, 2nd September
Equity
APLLTD
Alembic Pharma targets over 15 new product launches in US by FY27
Equity
APLLTD
Alembic Pharma Q1 revenue rises strongly year-on-year to Rs 2150 crores
Equity
APLLTD
Alembic Pharma Q1 EBITDA rises YoY but margin contracts modestly
Equity
APLLTD
Alembic Pharma Q1 consolidated net profit rises year-on-year on steady growth
Equity
APLLTD
Alembic Pharma gets USFDA nod for Prucalopride tablets, boosting US pipeline
Equity
APLLTD
Alembic Pharmaceuticals to host Q1 FY2026 earnings call on August 4
Equity
APLLTD
Alembic Pharma says USFDA warning letter to investigator has no operational impact
Equity
APLLTD
Alembic Pharmaceuticals sees Rs 34.08 crore NSE block trade at premium price
Equity
APLLTD
Alembic Pharma gains USFDA final nod for Dapsone Gel, 5 percent
Equity
APLLTD
Alembic Pharma gets USFDA final approval for Oseltamivir oral suspension
Equity
APLLTD
Alembic Pharmaceuticals: Gets Tentative Approval From Usfda For Binimetinib Tablet, Which Has Us Sales Of $26.00 Crores.
Equity
APLLTD
Alembic Pharmaceuticals gains on getting USFDA’s final approval for Tretinoin Cream
Equity
APLLTD
Alembic Pharmaceuticals gets USFDA’s final approval for Tretinoin Cream
Equity
APLLTD
Alembic Pharma gets USFDA final nod for tretinoin cream launch
Equity
APLLTD
Alembic Pharmaceuticals informs about press release
Equity
APLLTD
Alembic Pharmaceuticals gets USFDA’s tentative nod for Larotrectinib Capsules
Equity
APLLTD
Alembic Pharma gets tentative USFDA approval for Larotrectinib capsules
Equity
APLLTD
Alembic Pharma to acquire 45 percent stake in new Canadian pharma entity
Equity
APLLTD
Alembic Pharmaceuticals rises on getting USFDA's final approval for Haloperidol tablets
Equity
APLLTD